Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.62 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087772 | 0.99 | SLC6A4 (0.63) | SLC6A4HTR1ARORCIRAK4DRD1 | |
| SCHEMBL6088606 | 0.90 | SLC6A4 (0.64) | SLC6A4HTR1AIRAK4 | |
| SCHEMBL6087919 | 0.79 | SLC6A4 (0.60) | SLC6A4HTR1ARORCIRAK4DRD1 | |
| SCHEMBL6087601 | 0.79 | SLC6A4 (0.60) | SLC6A4HTR1ARORCDRD1SLC6A2 | |
| SCHEMBL6087738 | 0.77 | SLC6A4 (1.00) | SLC6A4HTR1ADRD1SLC6A2HTR1B | |
| SCHEMBL6087393 | 0.76 | SLC6A4 (0.62) | SLC6A4HTR1ARORC | |
| SCHEMBL6088870 | 0.76 | SLC6A4 (0.62) | SLC6A4HTR1ARORCDRD1SLC6A2 | |
| SCHEMBL6087082 | 0.76 | SLC6A4 (1.00) | SLC6A4HTR1ADRD1SLC6A2HTR1B | |
| SCHEMBL6087254 | 0.76 | SLC6A4 (0.62) | SLC6A4HTR1ARORCDRD1SLC6A2 | |
| SCHEMBL6636075 | 0.75 | SLC6A4 (0.53) | SLC6A4HTR1ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049314-B2 | Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | claimed |
| US-20040077705-A1 | Cyclopentyl indole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | claimed |
| WO-2004026236-A2 | CYCLOPENTYL INDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-7049314-B2 | Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077705-A1 | Cyclopentyl indole derivatives | HTR5A, TPH1, TPH2 | SLC6A4 11/4885HTR1A 4/4885RORC 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.